Annexon, Inc. ANNX
4.29 USD +0.05 (+1.30%)
Nov 10, 2026, 3:49 PM EST
4.11 Day range 4.37
2.54 52-week range 7.18
- YTD
- -14.64%
- 1 year
- +43.79%
News
benzinga.com Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 32.43 percent increase over losses of $(0.37) per…
marketbeat.com Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug Annexon NASDAQ: ANNX said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of…
seekingalpha.com Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript Annexon, Inc. (ANNX) Discusses Vonaprument Phase III ARCHER II Trial in Geographic Atrophy Transcript
benzinga.com Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026.…
benzinga.com Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
benzinga.com HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.- benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
- benzinga.com Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34)…
benzinga.com Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…
benzinga.com Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved…
benzinga.com Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…- benzinga.com Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3 Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Underperform rating and announces Price Target of $3.
benzinga.com Needham Maintains Buy on Annexon, Raises Price Target to $25 Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.- benzinga.com Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people…
- benzinga.com Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7 Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
benzinga.com Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 37.84 percent increase over losses of $(0.37) per…
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com Annexon Q4 EPS $(0.28) Beats $(0.32) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.32) by 11.11 percent. This is a 15.15 percent increase over losses of $(0.33) per…
benzinga.com Alpha Buying: Managing Biotech Risk With Insider Clues - benzinga.com Annexon Highlights 2026 Milestones With Tanruprubart MAA Filing, Vonaprument Phase 3 Data In Dry AMD, ANX1502 Proof‑of‑Concept Readout, Snd Strong Cash Position Funding Into 2027 Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026Vonaprument Pivotal Phase 3…
- benzinga.com Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of CareBLA Submission with U.S./European Data from FORWARD Trial Planned in 2026BRISBANE, Calif., Jan. 08, 2026…
- benzinga.com Chardan Capital Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $16 Chardan Capital analyst Daniil Gataulin initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $16.
- benzinga.com Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17 Clear Street analyst Bill Maughan initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $17.
- benzinga.com Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $27 Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $27.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $14 Price Target HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $14 price target.
- benzinga.com Annexon Q2 EPS $(0.34) Beats $(0.37) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 7.1 percent. This is a 47.83 percent decrease over losses of $(0.23) per…
- benzinga.com Annexon Announces That The European Medicines Agency Has Selected Vonaprument To Participate In The Product Development Coordinator Pilot New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence PlanningVonaprument Selected by EMA as One of ~20…
- benzinga.com Annexon Presents Data Highlighting Outcomes With Tanruprubart At 2025 Peripheral Nerve Society Annual Meeting First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of…
benzinga.com Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14 HC Wainwright & Co. analyst Andrew Fein maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $20 to $14.
benzinga.com Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com Needham Maintains Buy on Annexon, Lowers Price Target to $11 Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and lowers the price target from $16 to $11.
- benzinga.com Annexon Q1 EPS $(0.37) Misses $(0.29) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 76.19 percent decrease over losses of $(0.21)…
benzinga.com Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints.- benzinga.com Annexon Says Tanruprubart Met The Primary Endpoint; Demonstrates Rapid, Durable Recovery and Superior Efficacy In First Placebo-Controlled Phase 3 GBS Trial, Showing Significant Improvement In Motor Function, Mobility, and Disability Measures Over Placebo With No New Safety Signals First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation
- benzinga.com Annexon To Present Pivotal Data On First Potential Targeted Therapy For Guillain-Barré Syndrome And Showcases New GBS Education Campaign At AAN 2025 Annual Meeting Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBSDisease Education…
- benzinga.com Reported Earlier, Annexon Spotlights First-in-Class ANX005 Phase 3 Results For GBS And Launches 'Move GBS Forward' Initiative At AAN Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Needham Reiterates Buy on Annexon, Maintains $16 Price Target Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
- benzinga.com Annexon Announces 2025 Outlook, ANX005 Targets Guillain-Barré Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026 ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA SubmissionANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
- benzinga.com Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBSANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
- benzinga.com Needham Reiterates Buy on Annexon, Maintains $16 Price Target Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
- benzinga.com Annexon Q3 EPS $(0.25) Beats $(0.31) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.31) by 19.35 percent. This is a 41.86 percent increase over losses of $(0.43) per…
- benzinga.com Reported Earlier, Annexon Presents Phase 2 Data On ANX007 In Dry AMD Patients With Less Advanced GA At AAO 2024 Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data…